A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease

Affiliations

¹ Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
² Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: johntis@nhlbi.nih.gov.

Editorial

Alexis Leonard et al. Mol Ther. 2021.

. 2021 Apr 7;29(4):1355-1356.

doi: 10.1016/j.ymthe.2021.03.010. Epub 2021 Mar 19.

¹ Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
² Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: johntis@nhlbi.nih.gov.

No abstract available

Conflict of interest statement

J.F.T. is a principal investigator on ClinicalTrials.gov: NCT02140554 and A.L. is a co-investigator on ClinicalTrials.gov: NCT04293185.

1. Press Release . 2021. bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease. Business Wire, February 16, 2021.https://www.businesswire.com/news/home/20210216005442/en/
1. Hsieh M.M., Bonner M., Pierciey F.J., Uchida N., Rottman J., Demopoulos L., Schmidt M., Kanter J., Walters M.C., Thompson A.A. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4:2058–2063. - PMC - PubMed
1. Brunson A., Keegan T.H.M., Bang H., Mahajan A., Paulukonis S., Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130:1597–1599. - PMC - PubMed
1. Eapen M., Brazauskas R., Walters M.C., Bernaudin F., Bo-Subait K., Fitzhugh C.D., Hankins J.S., Kanter J., Meerpohl J.J., Bolaños-Meade J. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6:e585–e596. - PMC - PubMed
1. Li Y., Maule J., Neff J.L., McCall C.M., Rapisardo S., Lagoo A.S., Yang L.H., Crawford R.D., Zhao Y., Wang E. Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod. Pathol. 2019;32:1712–1726. - PubMed